Episode 290: PREMIUM – Empagliflozin and the EMPA-REG OUTCOME study
Submitted by JPM on Tue, 2015-10-06 14:51.
In episode 290, James and Mike address listener demands for a discussion on the latest diabetes outcomes trial that looked at empagliflozin, a new class of medications for type-2 diabetes. This study actually showed the group who received this new drug had a reduction in CVD events and other clinically important outcomes.